<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04017364</url>
  </required_header>
  <id_info>
    <org_study_id>SI-DN-MALAYSIA</org_study_id>
    <nct_id>NCT04017364</nct_id>
  </id_info>
  <brief_title>Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter Malaysia</brief_title>
  <acronym>SCBDNMAL</acronym>
  <official_title>Treatment of Coronary De-novo Stenosis by a Sirolimus Coated Balloon or a Paclitaxel Coated Balloon Catheter</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Saarland</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Saarland</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To examine the treatment of coronary de-novo stenosis with a sirolimus coated balloon versus
      a paclitaxel coated balloon
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To examine the treatment of coronary de-novo stenosis with a sirolimus coated balloon versus
      a paclitaxel coated balloon. Prospective, multicenter, randomized, single-blind, 70 patients.
      Experimental intervention: Predilatation of coronary de-novo stenosis followed by a sirolimus
      coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²). Control intervention: Predilatation of
      coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon
      (paclitaxel 3.0 μg/mm²). Follow-up per patient: 30 days telephone call; 6 months angiographic
      + 12 months. clinical follow up.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">October 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2021</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>late lumen loss in-segment</measure>
    <time_frame>6 months</time_frame>
    <description>angiographic minimal lumen diameter in-segment at 6 months minus minimal lumen diameter at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedural success</measure>
    <time_frame>5 days</time_frame>
    <description>combined endpoint of: &lt; 30% final diameter stenosis, no flow-limiting dissection (type C or higher), TIMI III flow, and the absence of in-hospital MACE</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MACE</measure>
    <time_frame>at 6 and at 12 months</time_frame>
    <description>combined endpoint of: cardiac death, target vessel myocardial infarction, and TLR target lesion revascularization in-hospital at 6 and at 12 months</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>PTCA of coronary de novo lesion PCB</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Predilatation of coronary de-novo stenosis followed by a SeQuent®Please or SeQuent®Please Neo balloon (paclitaxel 3.0 μg/mm²)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PTCA of coronary de novo lesion SCB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Predilatation of coronary de-novo stenosis followed by a sirolimus coated SeQuent®SCB balloon (sirolimus 4.0 μg/mm²)</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>PCB PTCA</intervention_name>
    <description>Predilatation of coronary de-novo stenosis followed by a PCB</description>
    <arm_group_label>PTCA of coronary de novo lesion PCB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SCB PTCA</intervention_name>
    <description>Predilatation of coronary de-novo stenosis followed by a SCB</description>
    <arm_group_label>PTCA of coronary de novo lesion SCB</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical evidence of stable or unstable angina or a positive functional study

          -  Patients with significant coronary de-novo stenosis (≥ 70% diameter stenosis or
             intermediate ≥ 50% to &lt;70% diameter stenosis with positive functional test or symptom
             of ischemia)

          -  Successful lesion preparation (no flow-limiting dissection or a residual stenosis &gt;
             30%)

        Exclusion Criteria:

          -  Acute myocardial infarction within the past 72 hours (STEMI or NSTEMI)

          -  Intolerance and / or allergy to Sirolimus

          -  Intolerance or allergy to Paclitaxel and/or the delivery matrix (main ingredient:

        iopromide)

          -  Patients with an ejection fraction of &lt; 30 %

          -  Reference vessel diameter (RVD) &lt; 2.5 mm

          -  Contraindication for whichever necessary accompanying medication
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Sabah Heart Centre, Queen Elizabeth Hospital II</name>
      <address>
        <city>Kota Kinabalu</city>
        <zip>88300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Liew Houng Bang, MD</last_name>
      <phone>+6019-8172269</phone>
      <email>hbliew22@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sarawak Heart Centre</name>
      <address>
        <city>Kota Samarahan</city>
        <zip>94300</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ong Tiong Kiam, MD</last_name>
      <phone>+60198875348</phone>
      <email>ongtk@moh.gov.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Heart Institute</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50400</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Amin Ariff Nuruddin, MD</last_name>
      <phone>+6 012 - 320 8658</phone>
      <email>dramin@ijn.com.my</email>
    </contact>
    <investigator>
      <last_name>Amin Ariff Nuruddin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cardio Vascular Sentral</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50470</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosli Mohd Ali, MD</last_name>
      <phone>+ 603 2276 7096</phone>
      <email>rosliali@cvskl.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>50603</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wan Azman, MD</last_name>
      <phone>+6 03 - 79492429</phone>
      <email>wanazman@ummc.edu.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Pulau Pinang</name>
      <address>
        <city>Penang</city>
        <zip>10990</zip>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muhamad Ali Sk Abdul Kader, MD</last_name>
      <phone>+60 13 4355 601</phone>
      <email>mdali_sheikh@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <results_reference>
    <citation>Ali RM, Abdul Kader MASK, Wan Ahmad WA, Ong TK, Liew HB, Omar AF, Mahmood Zuhdi AS, Nuruddin AA, Schnorr B, Scheller B. Treatment of Coronary Drug-Eluting Stent Restenosis by a Sirolimus- or Paclitaxel-Coated Balloon. JACC Cardiovasc Interv. 2019 Mar 25;12(6):558-566. doi: 10.1016/j.jcin.2018.11.040.</citation>
    <PMID>30898253</PMID>
  </results_reference>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 3, 2019</study_first_submitted>
  <study_first_submitted_qc>July 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 12, 2019</study_first_posted>
  <last_update_submitted>July 11, 2019</last_update_submitted>
  <last_update_submitted_qc>July 11, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 12, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>drug coated balloon</keyword>
  <keyword>Paclitaxel</keyword>
  <keyword>sirolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

